Evidence map›Paper›PMID 36275757›Full record

ArticleFrontiers in immunology2022

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology.

Fabrice Cognasse, Hind Hamzeh-Cognasse, Anne-Claire Duchez, Natalia Shurko, Marie-Ange Eyraud, Charles-Antoine Arthaud, Amélie Prier, Marco Heestermans, Olivier Hequet, Brigitte Bonneaudeau and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 2 countries.

Fabrice CognasseEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Hind Hamzeh-CognasseUniversité Jean Monnet, Mines Saint-Étienne, INSERM (Institut National de la Santé et de la Recherche Médicale), U 1059 Sainbiose, (SAnté INgéniérie BIOlogie St-Etienne), Saint-Étienne, France.
Anne-Claire DuchezEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Natalia ShurkoInstitute of Blood Pathology and Transfusion Medicine NAMS (National Academy of Medical Sciences) of Ukraine, Lviv, Ukraine.
Marie-Ange EyraudEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Charles-Antoine ArthaudEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Amélie PrierEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Marco HeestermansEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Olivier HequetEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Brigitte BonneaudeauEtablissement Français du Sang, La Plaine St Denis, France.
Sandrine Rochette-EribonEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Françoise TeyssierEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Valérie Barlet-ExcoffierEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Patricia ChavarinEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Dominique LegrandEtablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
Pascale RichardEtablissement Français du Sang, La Plaine St Denis, France.
Pascal MorelEtablissement Français du Sang, La Plaine St Denis, France.
Nuala MooneyHuman Immunology, Pathophysiology and Immunotherapy, INSERM (Institut National de la Santé et de la Recherche Médicale) U976, Paris, France.
Pierre TiberghienEtablissement Français du Sang, La Plaine St Denis, France.
Établissement Français du Sang · FRUniversité Jean Monnet · FRBiologie, ingénierie et imagerie pour l'Ophtalmologie · FRInserm · FRCentre International de Recherche en Infectiologie · FRHôpital Saint-Louis · FRInstitute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine · UAMines Saint-Étienne · FRUnité de recherche sur les maladies cardiovasculaires et métaboliques · FRUniversité de franche-comté · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood products in therapeutic transfusion are now commonly acknowledged to contain biologically active constituents during the processes of preparation. In the midst of a worldwide COVID-19 pandemic, preliminary evidence suggests that convalescent plasma may lessen the severity of COVID-19 if administered early in the disease, particularly in patients with profound B-cell lymphopenia and prolonged COVID-19 symptoms. This study examined the influence of photochemical Pathogen Reduction Treatment (PRT) using amotosalen-HCl and UVA light in comparison with untreated control convalescent plasma (n= 72 - paired samples) - cFFP, regarding soluble inflammatory factors: sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha and

Indexed as

COVID-19PandemicsCOVID-19 SerotherapyEndothelial CellsFurocoumarinsHumansInterleukin-10Interleukin-18Interleukin-1betaInterleukin-6Interleukin-8TechnologyTumor Necrosis Factor-alphaUltraviolet RaysamotosalenFurocoumarinsInterleukin-10Interleukin-18Interleukin-1betaInterleukin-6Interleukin-8Tumor Necrosis Factor-alphaconvalescent plasmaCOVID-19cytokineendothelial cellinflammation

Identifiers

PMID36275757
PMCPMC9585295
OpenAlexW4303183177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.